Your browser doesn't support javascript.
loading
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
Hertler, Caroline; Felsberg, Jörg; Gramatzki, Dorothee; Le Rhun, Emilie; Clarke, Jennifer; Soffietti, Riccardo; Wick, Wolfgang; Chinot, Olivier; Ducray, François; Roth, Patrick; McDonald, Kerrie; Hau, Peter; Hottinger, Andreas F; Reijneveld, Jaap; Schnell, Oliver; Marosi, Christine; Glantz, Michael; Darlix, Amélie; Lombardi, Giuseppe; Krex, Dietmar; Glas, Martin; Reardon, David A; van den Bent, Martin; Lefranc, Florence; Herrlinger, Ulrich; Razis, Evangelia; Carpentier, Antoine F; Phillips, Samuel; Rudà, Roberta; Wick, Antje; Tabouret, Emeline; Meyronet, David; Maurage, Claude-Alain; Rushing, Elisabeth; Rapkins, Robert; Bumes, Elisabeth; Hegi, Monika; Weyerbrock, Astrid; Aregawi, Dawit; Gonzalez-Gomez, Christian; Pellerino, Alessia; Klein, Martin; Preusser, Matthias; Bendszus, Martin; Golfinopoulos, Vassilis; von Deimling, Andreas; Gorlia, Thierry; Wen, Patrick Y; Reifenberger, Guido; Weller, Michael.
Afiliación
  • Hertler C; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland; Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Felsberg J; Institute of Neuropathology, Medical Faculty, Heinrich Heine University and University Hospital Düsseldorf, Düsseldorf, Germany.
  • Gramatzki D; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland; Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Le Rhun E; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland; Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland; Service de neurochirurgie, CHU Lille, F-59000 Lille, France; Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire
  • Clarke J; UCSF Department of Neurological Surgery, Division of Neuro-Oncology, 400 Parnassus Avenue, A-808 San Francisco, CA, USA.
  • Soffietti R; Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital, Turin, Italy.
  • Wick W; Neurology Clinic, University of Heidelberg, Heidelberg, Germany; CCU Neurooncology, DKFZ, Heidelberg, Germany.
  • Chinot O; Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service de Neuro-Oncologie, Marseille, France.
  • Ducray F; Departments of Neuro-Oncology, Hospices Civils de Lyon, Centre de recherche en Cancérologie de Lyon, Lyon, France; INSERM U1052, CNRS UMR 5286, Université Lyon 1, Lyon, France.
  • Roth P; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland; Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • McDonald K; Cure Brain Cancer Neuro-Oncology group, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia.
  • Hau P; Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, Regensburg, Germany.
  • Hottinger AF; Lundin Family Brain Tumor Center, Departments of Oncology & Clinical Neurosciences, CHUV Lausanne University Hospital, Lausanne, Switzerland.
  • Reijneveld J; Amsterdam UMC location Vrije Universiteit Amsterdam, Neurology, Brain Tumor Center Amsterdam, Amsterdam, the Netherlands; Department of Neurology, Stichting Epilepsie Instellingen Nederland, Heemstede, the Netherlands.
  • Schnell O; Department of Neurosurgery, Medical Center- University of Freiburg, Freiburg, Germany.
  • Marosi C; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Glantz M; Departments of Neurosurgery and Oncology, Penn State College of Medicine - Hershey Medical Center, Hershey, PA, USA.
  • Darlix A; Department of Medical Oncology, Institut régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; Institut de Génomique Fonctionnelle, INSERM, CNRS, University of Montpellier, Montpellier, France.
  • Lombardi G; Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128 Padua, Italy.
  • Krex D; Department of Neurosurgery, University Hospital Carl Gustav Carus, TU, Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, Germany.
  • Glas M; Division of Clinical Neurooncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany; German Cancer Consortium (DKTK), Partner Site University Medicine Essen, Essen, Germany.
  • Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
  • van den Bent M; Brain Tumor Center at ErasmusMC Cancer Institute, Erasmus University Hospital Rotterdam, Rotterdam, the Netherlands.
  • Lefranc F; Department of Neurosurgery, Hôpital Universitaire de Bruxelles HUB, Brussels, Belgium.
  • Herrlinger U; Division of Clinical Neurooncology, Department of Neurology and Center of Integrated Oncology, University of Bonn, Bonn, Germany.
  • Razis E; Hygeia Hospital, Athens, Greece.
  • Carpentier AF; Department of Neurology, Hôpital Saint-Louis, Université Paris Cité, APHP, Paris, France.
  • Phillips S; UCSF Department of Neurological Surgery, Division of Neuro-Oncology, 400 Parnassus Avenue, A-808 San Francisco, CA, USA.
  • Rudà R; Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital, Turin, Italy.
  • Wick A; Neurology Clinic, University of Heidelberg, Heidelberg, Germany.
  • Tabouret E; Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service de Neuro-Oncologie, Marseille, France.
  • Meyronet D; INSERM U1052, CNRS UMR 5286, Université Lyon 1, Lyon, France; Neuropathology, Hospices Civils de Lyon, Centre de recherche en Cancérologie de Lyon, Lyon, France.
  • Maurage CA; Service de biochimie et biologie moléculaire, CHU Lille, F-59000 Lille France.
  • Rushing E; Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland.
  • Rapkins R; Cure Brain Cancer Neuro-Oncology group, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia.
  • Bumes E; Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, Regensburg, Germany.
  • Hegi M; Neuroscience Research Center and Service of Neurosurgery & Lundin Family Brain Tumor Center, Lausanne University Hospital and University of Lausanne, 1066 Epalinges, Switzerland.
  • Weyerbrock A; Department of Neurology, Stichting Epilepsie Instellingen Nederland, Heemstede, the Netherlands.
  • Aregawi D; Departments of Neurosurgery and Oncology, Penn State College of Medicine - Hershey Medical Center, Hershey, PA, USA.
  • Gonzalez-Gomez C; UCSF Department of Neurological Surgery, Division of Neuro-Oncology, 400 Parnassus Avenue, A-808 San Francisco, CA, USA.
  • Pellerino A; Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital, Turin, Italy.
  • Klein M; Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Psychology, Amsterdam, the Netherlands.
  • Preusser M; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Bendszus M; Department of Neuroradiology, University Hospital of Heidelberg, Heidelberg, Germany.
  • Golfinopoulos V; EORTC Headquarters, Brussels, Belgium.
  • von Deimling A; Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany; CCU Neuropathology, German Cancer Center (DKFZ), Heidelberg, Germany.
  • Gorlia T; EORTC Headquarters, Brussels, Belgium.
  • Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
  • Reifenberger G; Institute of Neuropathology, Medical Faculty, Heinrich Heine University and University Hospital Düsseldorf, Düsseldorf, Germany; German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.
  • Weller M; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland; Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland. Electronic address: michael.weller@usz.ch.
Eur J Cancer ; 189: 112913, 2023 08.
Article en En | MEDLINE | ID: mdl-37277265
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Suiza